Regulatory watch: The orphan drug pipeline in Europe

Nature Reviews Drug Discovery

Volumn 15, Issue 6, 2016, Pages 376-

  Morel, Thomas ^a   Lhoir, André ^b   Picavet, Eline ^a   Mariz, Segundo ^c   Sepodes, Bruno ^d   Llinares, Jordi ^c   Cassiman, David ^e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Federal Agency for Medicines and Health Products Belgium   (Belgium)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ACROMEGALY; CUSHING SYNDROME; DRUG MARKETING; DRUG RESEARCH; DUCHENNE MUSCULAR DYSTROPHY; EPIDERMOLYSIS BULLOSA; EUROPE; GENETIC DISORDER; HEMOPHILIA; HUMAN; MEDICAL SOCIETY; MUCOPOLYSACCHARIDOSIS; NOTE; PREVALENCE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; RARE DISEASE; SYSTEMIC SCLEROSIS; DRUG MANUFACTURE; LEGISLATION AND JURISPRUDENCE; RARE DISEASES;

EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84973360937     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2016.96     Document Type: Note

References (0)